[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632259":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":135,"collaborators":25,"id":137,"slug":138,"hasResults":139,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":139,"sex":145,"minAge":146,"maxAge":25,"enrollmentInfo":147,"targetDuration":25,"studyType":150,"phases":151,"briefSummary":153,"conditions":154,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Kardigan, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tonlamarsen","EXPERIMENTAL","3 doses active drug will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)",[13],"Drug: Tonlamarsen",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","3 doses of placebo will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tonlamarsen will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Kardigan Clinical Study Information Team","CONTACT","+1-877-310-5135","clinicaltrials@kardigan.bio",[36,52,65,76,88,100,112,124],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Western Nephrology and Metabolic Bone Disease, PC - Arvada","RECRUITING","Arvada","Colorado","80002","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-105.08748,39.80276,{"lat":48,"lon":47},[51],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"facility":53,"status":38,"city":54,"state":55,"zip":56,"country":42,"countryCode":43,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Homestead Associates in Research","Homestead","Florida","33033",{"type":45,"coordinates":58},[59,60],-80.47756,25.46872,{"lat":60,"lon":59},[63],{"name":31,"role":32,"phone":64,"phoneExt":25,"email":34},"1-877-310-5135",{"facility":66,"status":38,"city":67,"state":55,"zip":68,"country":42,"countryCode":43,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Progressive Medical Research","Port Orange","32127",{"type":45,"coordinates":70},[71,72],-80.99561,29.13832,{"lat":72,"lon":71},[75],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"facility":77,"status":38,"city":78,"state":79,"zip":80,"country":42,"countryCode":43,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Richmond University Medical Center (RUMC)","Staten Island","New York","10310",{"type":45,"coordinates":82},[83,84],-74.13986,40.56233,{"lat":84,"lon":83},[87],{"name":31,"role":32,"phone":64,"phoneExt":25,"email":34},{"facility":89,"status":38,"city":90,"state":91,"zip":92,"country":42,"countryCode":43,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Research Innovations, LLC","Beavercreek","Ohio","05431",{"type":45,"coordinates":94},[95,96],-84.06327,39.70923,{"lat":96,"lon":95},[99],{"name":31,"role":32,"phone":64,"phoneExt":25,"email":34},{"facility":101,"status":38,"city":102,"state":103,"zip":104,"country":42,"countryCode":43,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Chattanooga Research & Medicine CHARM","Chattanooga","Tennessee","37404",{"type":45,"coordinates":106},[107,108],-85.30968,35.04563,{"lat":108,"lon":107},[111],{"name":31,"role":32,"phone":64,"phoneExt":25,"email":34},{"facility":113,"status":38,"city":114,"state":115,"zip":116,"country":42,"countryCode":43,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Laguna Clinical Research Associates","Laredo","Texas","78041",{"type":45,"coordinates":118},[119,120],-99.50754,27.50641,{"lat":120,"lon":119},[123],{"name":31,"role":32,"phone":64,"phoneExt":25,"email":34},{"facility":125,"status":38,"city":126,"state":115,"zip":127,"country":42,"countryCode":43,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Baylor Scott and White Research Institute - Temple","Temple","76502",{"type":45,"coordinates":129},[130,131],-97.34278,31.09823,{"lat":131,"lon":130},[134],{"name":31,"role":32,"phone":64,"phoneExt":25,"email":34},{"type":136,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100632259","phase-2-study-of-efficacy-and-safety-of-tonlamarsen-in-participants-with-a-recent-hospitalization-and-a-concurrent-episode-of-acute-severe-hypertension-100632259",false,"NCT07511361","Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","KARDINAL-ASH","Key Inclusion Criteria:\n\n* Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg\u002Fm2\n* Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and\u002For treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and\u002For DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization\n* At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg\n* Presence of established cardiovascular or renal disease\n\nKey Exclusion Criteria:\n\n* Has known history of secondary hypertension\n* Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated)\n* Has abnormal thyroid function with clinical significance\n* Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening\n* History of and\u002For obvious clinical signs or symptoms of cirrhosis or other significant liver disease\n* Alanine aminotransferase or aspartate aminotransferase \\>2 x upper limit of normal\n* Most recent hospitalization was for non-cardiovascular or non-renal conditions","ALL","18 Years",{"count":148,"type":149},140,"ESTIMATED","INTERVENTIONAL",[152],"PHASE2","The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.",[155,156,157,158],"Hypertension","Acute Severe Hypertension","Hypertensive Emergency","Hypertensive Urgency","2026-06-29",{"date":161,"type":162},"2026-07-01","ACTUAL",{"date":164,"type":162},"2026-06-23",{"date":166,"type":149},"2027-02",{"name":5,"class":6},8]